Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

327.94USD
15 Dec 2017
Change (% chg)

$4.39 (+1.36%)
Prev Close
$323.55
Open
$328.61
Day's High
$330.06
Day's Low
$322.87
Volume
1,054,357
Avg. Vol
476,607
52-wk High
$348.65
52-wk Low
$244.31

Summary

Name Age Since Current Position

Stelios Papadopoulos

68 2014 Independent Chairman of the Board

Michel Vounatsos

55 2017 Chief Executive Officer, Director

Gregory Covino

51

Ginger Gregory

49 2017 Chief Human Resource Officer, Executive Vice President

Kenneth Di Pietro

58 2012 Executive Vice President - Human Resources

Susan Alexander

60 2011 Executive Vice President, Chief Legal Officer and Corporate Secretary

Michael Ehlers

48 2016 Executive Vice President, Head - Research and Development

Chirfi Guindo

2017 Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation

Adriana Karaboutis

54 2014 Executive Vice President - Technology , Business Solutions and Corporate Affairs

Jean-Paul Kress

51 2017 Executive Vice President, President - International and Head of Global Therapeutic Operations

Paul McKenzie

51 2016 Executive Vice President - Pharmaceutical Operations & Technology

Alfred Sandrock

59 2015 Executive Vice President - Neurology Discovery and Development and Chief Medical Officer

Mark Hernon

2017 Senior Vice President, Chief Information Officer

Anirvan Ghosh

2017 Senior Vice President - Research and Early Development

Sanjay Jariwala

2017 Senior Vice President - Worldwide Medical

Camille Lee

2017 Senior Vice President - Alzheimer's Therapeutic Area

Catherine Steele

2017 Senior Vice President - Corporate Affairs

Anabella Villalobos

2017 Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS)

Alexander Denner

47 2009 Independent Director

Caroline Dorsa

57 2010 Independent Director

Nancy Leaming

69 2008 Independent Director

Richard Mulligan

62 2009 Independent Director

Robert Pangia

66 1997 Independent Director

Brian Posner

55 2008 Independent Director

Eric Rowinsky

60 2010 Independent Director

Lynn Schenk

72 1995 Independent Director

Stephen Sherwin

68 2010 Independent Director

Biographies

Name Description

Stelios Papadopoulos

Dr. Stelios B. Papadopoulos, Ph.D. is the Independent Chairman of the Board of the Company. Dr. Papadopoulos has served as one of our directors since 2008 and as our independent Chairman since June 2014. Dr. Papadopoulos also serves as the Chairman of Regulus Therapeutics Inc., a biopharmaceutical company, and Exelixis, Inc., a drug discovery and development company that he co-founded in 1994. Previously, he was an investment banker with Cowen & Co., LLC, a financial services company, focusing on the biotechnology and pharmaceutical sectors, from 2000 until his retirement as Vice Chairman in August 2006. Prior to joining Cowen & Co., Dr. Papadopoulos served for 13 years as an investment banker at PaineWebber, Inc., a financial services company, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology.

Michel Vounatsos

Mr. Michel Vounatsos is the Chief Executive Officer and Director of the company. Mr. Vounatsos has served as our Chief Executive Officer and one of our directors since January 2017. Prior to that, from April 2016 to December 2016, he served as our Executive Vice President, Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc., a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health, and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers, and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy. Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

Gregory Covino

Mr. Gregory F. Covino is no longer Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance of the Company., effective June 30, 2017. He currently serves as Chief Accounting Officer, Vice President - Finance of Biogen Inc. Mr. Covino has served as the Company’s Vice President and Chief Accounting Officer since April 2012. Prior to that, Mr. Covino served at Boston Scientific Corporation, a medical device company, as Vice President, Corporate Analysis and Control Executive since March 2010, having responsibility for the company’s internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company’s international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporate Accounting from 1999 to 2002.

Ginger Gregory

Ms. Ginger Gregory, Ph.D. is appointed as Chief Human Resource Officer, Executive Vice President of the company effective July 17. 2017. She most recently the Chief Human Resources Officer at Shire Pharmaceuticals, brings more than 20 years of human resources experience to Biogen. She will now lead the company's global HR function and organizational strategy and will serve as a member of Biogen's Executive Committee. At Shire, Gregory helped lead the integration of several acquired companies, including Baxalta, while consolidating multiple business units into a single organization while overseeing the overhaul of the company's HR systems globally. Her industry experience also includes HR leadership roles at Bristol-Myers Squibb, Novo Nordisk, and Novartis, working across commercial, R&D and corporate functions. She also served as chief human resources officer at Dunkin' Brands.

Kenneth Di Pietro

Mr. Kenneth A. Di Pietro is Executive Vice President - Human Resources of Biogen Inc., since January 2012. Mr. DiPietro has served as our Executive Vice President, Human Resources since January 2012. Mr. DiPietro joined Biogen from Lenovo Group, a technology company, where he served as Senior Vice President, Human Resources from 2005 to June 2011. From 2003 to 2005, he served as Corporate Vice President, Human Resources at Microsoft Corporation, a technology company. From 1999 to 2002, Mr. DiPietro worked as Vice President, Human Resources at Dell Inc., a technology company. Prior to that, he spent 17 years at PepsiCo, a food and beverage company, serving in a range of human resource and general management positions. He received his B.S. in Industrial and Labor Relations from Cornell University,

Susan Alexander

Ms. Susan H. Alexander, Esq., is the Executive Vice President, Chief Legal Officer and Corporate Secretary of Biogen Inc., since December 2011. Ms. Alexander has served as our Executive Vice President, Chief Legal Officer and Corporate Secretary since December 2011. Prior to that, from 2006 to December 2011, Ms. Alexander served as our Executive Vice President, General Counsel and Corporate Secretary. From 2003 to January 2006, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.

Michael Ehlers

Dr. Michael D. Ehlers, M.D., Ph.D. is Executive Vice President, Head - Research and Development of the Company. Dr. Ehlers has served as our Executive Vice President, Head of R&D since May 2016. Prior to joining Biogen, Dr. Ehlers served in leadership positions at Pfizer, Inc., including Senior Vice President & Head BioTherapeutics R&D and Chief Scientific Officer, Neuroscience & Pain. Prior to that, Dr. Ehlers was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center. He is the recipient of numerous awards including the Eppendorf & Science Prize in Neurobiology, the John J. Abel Award in Pharmacology, the Society for Neuroscience Young Investigator Award, a National Institute of Mental Health MERIT Award, the National Alliance for Schizophrenia and Depression Distinguished Investigator Award, and the Massachusetts Medical Society Honored Business Leader Award. In 2013, Dr. Ehlers became the 11th recipient of the Thudichum Medal of the Biochemical Society of the United Kingdom. Past recipients include two Nobel laureates. Dr. Ehlers has authored over 100 scientific papers, has served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry, the Journal of Molecular and Cellular Neuroscience, and has sat on advisory committees of the National Institutes of Health. He holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine and has authored more than 100 scientific papers. He holds B.S in chemistry University of California Institute of Technology

Chirfi Guindo

Mr. Chirfi Guindo is Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation of the Company. Mr. Guindo brings 27 years of experience in the global pharmaceutical industry and has held several leadership positions at Merck (known as MSD outside Canada and the USA) in Canada, the USA, France, Africa and the Netherlands. He worked in several disciplines including Finance, Sales & Marketing, General Management and Global Strategy / Product Development in specialty, acute and hospital care. Most recently Mr. Guindo was President & Managing Director of Merck Canada. Mr. Guindo graduated with a degree in Engineering from Ecole Centrale de Paris (France) and obtained an MBA in Finance / Economics from New York University / Stern School of Business (USA).

Adriana Karaboutis

Ms. Adriana Karaboutis is Executive Vice President - Technology, Business Solutions and Corporate Affairs of Biogen Inc., since September 2014. Ms. Karaboutis has served as our Executive Vice President, Technology, Business Solutions and Corporate Affairs since December 2015 and prior to that served as our Executive Vice President, Technology and Business Solutions since joining Biogen in September 2014. Prior to that, Ms. Karaboutis was Vice President and Global Chief Information Officer of Dell, Inc., where she was responsible for leading a global IT organization focused on powering Dell as an end-to-end technology solutions provider. Prior to joining Dell in 2010, Ms. Karaboutis spent over 20 years at General Motors and Ford Motor Company in various international leadership positions including computer-integrated manufacturing, supply chain operations, and information technology. She received her B.S. in Computer Science in Wayne State University,

Jean-Paul Kress

Dr. Jean-Paul Kress, M.D., has been appointed as Executive Vice President, President - International and Head of Global Therapeutic Operations of the Company., effective June 19, 2017. Dr. Kress was most recently senior vice president, head of North America at Sanofi Genzyme, where he oversaw the multiple sclerosis, oncology, and immunology business units in the U.S. and Canada. Prior to his 2015 arrival at Sanofi Genzyme, he spent four years as president and chief executive officer of Sanofi Pasteur MSD leading a variety of functions, including sales and marketing, market access, supply chain support, and medical affairs. Dr. Kress holds graduate and post-graduate degrees in biochemistry and molecular and cellular pharmacology from Ecole normale superieure, Paris, and an M.D. from Faculte Necker-Enfants Malades, Paris. His industry experience also includes leadership roles with Eli Lilly, Abbott Laboratories, and Gilead Sciences.

Paul McKenzie

Dr. Paul McKenzie, Ph.D. is a Executive Vice President - Pharmaceutical Operations & Technology of the Company. Dr. McKenzie has served as our Executive Vice President, Pharmaceutical Operations and Technology since July 2016. Prior to that, from February 2016 to June 2016, he served as our Senior Vice President for Global Biologics Manufacturing & Technical Operations. Prior to joining Biogen, since 2008, Dr. McKenzie held a number of positions of increasing responsibility at Johnson & Johnson (J&J), including Vice President of R&D for J&J’s Ethicon business where he led the manufacturing and technical operations team responsible for internal and external manufacturing of Janssen’s pharmaceutical portfolio. He also ran global Development for Janssen R&D, helping to manage pipeline activities from discovery through clinical development and commercialization. Prior to J&J, Dr. McKenzie also held various R&D and manufacturing positions at Bristol-Myers Squibb and Merck & Co. Dr. McKenzie Recived B.S from the University of Pennsylvania and received his doctorate in chemical engineering from Carnegie Mellon University.

Alfred Sandrock

Dr. Alfred W. Sandrock, Jr. M.D. Ph.D. is Executive Vice President - Neurology Discovery and Development and Chief Medical Officer of Biogen Inc. Dr. Sandrock has served as our Chief Medical Officer and Executive Vice President of Neurology Discovery and Development since November 2015. Prior to that, Dr. Sandrock served as our Chief Medical Officer and Group Senior Vice President from May 2013 to October 2015, and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several senior executive positions since joining us in 1998, including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology. He received his B.A. in Human Biology from Stanford University, M.D. from Harvard Medical School, Ph.D. in Neurobiology from Harvard University and internship in Medicine, residency and chief residency in Neurology, and clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography) Massachusetts General Hospital.

Mark Hernon

Mr. Mark Hernon is Senior Vice President, Chief Information Officer of the Company. In his new role, Mr. Hernon will lead the global information technology (IT) organization and be responsible for accelerating and supporting Biogen's operations through delivery of innovative technology capabilities, systems, and tools that align with Biogen's corporate strategy. Mr. Hernon joins Biogen with more than 30 years of experience in IT and strategic leadership. In recent years with Takeda Pharmaceuticals, he was the Regional CIO for the Americas and Global Head of R&D, QA and HR Systems, as well as VP of Operations for the Cambridge, MA site. He was most recently the Global Head of R&D Site Strategy and Operations, where he led the global transformation of Takeda's R&D footprint. Mr. Hernon holds a BS and MS in Industrial and Management Engineering from Rensselaer Polytechnic Institute, and an MBA from the Lally School of Management at Rensselaer Polytechnic Institute

Anirvan Ghosh

Dr. Anirvan Ghosh, Ph.D., has been appointed as Senior Vice President - Research and Early Development of the Company, with effect form April 2017. Dr. Ghosh will lead Biogen's RED organization in the discovery and development of drug candidates from idea through proof of concept. Dr. Ghosh joins Biogen from E-Scape Bio, where he served as chief scientific officer. Prior to heading discovery efforts for Alzheimer's disease and neurodegenerative disorders at E-Scape Bio, he served as vice president, Global Head of Neuroscience Discovery and Biomarkers at Roche. In this capacity, Dr. Ghosh led research and drug discovery for programs addressing neurodegenerative diseases as well as neurodevelopmental and psychiatric disorders. Prior to joining industry, Dr. Ghosh served as a professor on the neuroscience faculties of the Johns Hopkins University and the University of California, San Diego. His academic research has focused on understanding how connections in the brain are established during development and how these connections may be affected in neurodevelopmental disorders. Dr. Ghosh received a BS in Physics from the California Institute of Technology, a Ph.D. in Neuroscience from Stanford University, and postdoctoral training at Harvard Medical School. He is the author of more than 90 scientific publications

Sanjay Jariwala

Dr. Sanjay Jariwala is Senior Vice President - Worldwide Medical of the Company. Dr. Jariwala joins Biogen from AstraZeneca Pharmaceuticals, where he held the roles of Vice President, Head of Strategy and Vice President of Infection, Neuroscience, Autoimmunity and Anti-thrombotics, Global Medical Affairs. During his time at AstraZeneca, he led the transformation of the Worldwide Medical Affairs Council, developed a strategic medical planning process to align commercial operations and R&D priorities, and created and established a new medical operating model for both medical strategy and execution at the global, regional, and local levels. Prior to AstraZeneca, Dr. Jariwala was Senior Vice President, Global Head of Business Development and a member of the Executive Committee at Vifor Pharma in Zurich, and prior to that at Aspreva Pharmaceuticals in Vancouver. His industry experience also includes several senior Medical Affairs and Clinical Development leadership roles at GlaxoSmithKline in the cardiovascular, metabolic, and urology therapy areas. Before moving to industry, he was a practicing physician for the National Health Service in the U.K. Dr. Jariwala holds a Master's degree in Medical Sciences from Christ's College, University of Cambridge, England. He received his medical degree and completed his medical training at the University of Cambridge, while based at Addenbrookes Hospital.

Camille Lee

Ms. Camille Lee is Senior Vice President - Alzheimer's Therapeutic Area of the company. She brings to Biogen more than 30 years of industry experience. In her most recent role as Senior Vice President, Diabetes & Obesity Marketing at Novo Nordisk, she led a team of more than 500 professionals while overseeing the marketing of all in-line and future brands as well as market access strategy. During her time in this position, Novo Nordisk successfully launched two brands that achieved leadership in their therapeutic areas.

Catherine Steele

Ms. Catherine Steele is appointed as Senior Vice President - Corporate Affairs of the company effective July 17. 2017. She most recently served as Global Head, Communications and Patient Relations at Novartis Pharmaceuticals, where she was responsible for corporate reputation and helping drive external, internal and executive communication strategies. She also led the company's social media and patient relations activities. Her career in the biopharma industry began at Roche, where she spent more than a decade in global communications and policy leadership roles.

Anabella Villalobos

Dr. Anabella Villalobos, Ph.D., serves as Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) of the Company. Dr. Villalobos joins Biogen from Pfizer Worldwide Research and Development where she most recently served as Vice President and Head of Medicinal Synthesis Technologies. With over 25 years of industry experience in the areas of neuroscience and medicinal chemistry, she has been instrumental in the development of clinical candidates for Alzheimer's disease, Parkinson's disease, schizophrenia, and pain. Before joining industry, Dr. Villalobos received a BS in Chemistry from the University of Panama, a Ph.D. in Medicinal Chemistry from The University of Kansas, and synthetic organic chemistry training at Yale University as a National Institutes of Health Postdoctoral Fellow.

Alexander Denner

Dr. Alexander J. Denner, Ph.D. is an Independent Director of the Company. Dr. Denner has served as one of our directors since 2009. Dr. Denner is a founding partner and Chief Investment Officer of Sarissa Capital Management LP. Sarissa Capital focuses on improving the strategies of companies to better provide shareholder value. From 2006 to 2011, Dr. Denner served as a Senior Managing Director at Icahn Capital. Prior to that, he served as a portfolio manager at Viking Global Investors and Morgan Stanley Investment Management.

Caroline Dorsa

Ms. Caroline D. Dorsa is an Independent Director of the Company. Ms. Dorsa has served as one of our directors since 2010. Ms. Dorsa served as the Executive Vice President and Chief Financial Officer of Public Service Enterprise Group Incorporated, a diversified energy company, from April 2009 until her retirement in October 2015, and served on its Board of Directors from 2003 to April 2009. From February 2008 to April 2009, she served as Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., a pharmaceutical company. From November 2007 to January 2008, Ms. Dorsa served as Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc., a life sciences company. From February 2007 to November 2007, she served as Senior Vice President and Chief Financial Officer of Avaya, Inc., a telecommunications company. From 1987 to January 2007, Ms. Dorsa held various financial and operational positions at Merck & Co., Inc., including Vice President and Treasurer, Executive Director of U.S. Customer Marketing and Executive Director of U.S. Pricing and Strategic Planning. Ms. Dorsa also serves as a director of Illumina, Inc., Intellia Therapeutics, Inc., and as a Trustee of the Goldman Sachs ETF Trust, the Goldman Sachs MLP and Energy Renaissance Fund, and the Goldman Sachs MLP Income Opportunities Fund, investment funds within the Goldman Sachs fund complex.

Nancy Leaming

Ms. Nancy L. Leaming is an Independent Director of the Company. Ms. Leaming has served as one of our directors since 2008. Ms. Leaming has been an independent consultant since 2005. From 2003 to 2005, she served as the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance. From 1986 to 2003, Ms. Leaming served in several executive positions at Tufts Health Plan, including President, Chief Operating Officer, and Chief Financial Officer.

Richard Mulligan

Prof. Dr. Richard C. Mulligan, Ph.D. is an Independent Director of the Company. Dr. Mulligan has served as one of our directors since 2009. He is currently a Portfolio Manager at Icahn Capital LP and, since 2013, the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School, after serving as the Mallinckrodt Professor of Genetics and Director of the Harvard Gene Therapy Initiative since 1996. Prior to that, he was Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research, and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was a founding partner of Sarissa Capital Management LP, an investment firm, from 2013 to 2016. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981.

Robert Pangia

Mr. Robert W. Pangia is an Independent Director of the Company. Mr. Pangia served as a director of the Company from 1997 to 2003 during the period the Company was operated as IDEC Pharmaceuticals, and has served as a director since 2003 following IDEC’s merger with Biogen Inc. Mr. Pangia has been a partner in Ivy Capital Partners, LLC, the general partner of Ivy Healthcare Capital, L.P., a private equity fund specializing in healthcare investments, since 2003. From 2011 to 2016 he was also the Chief Executive Officer of Ivy Sports Medicine, LLC, a medical device company. From October 2007 to October 2009, he also served as the Chief Executive Officer of Highlands Acquisition Corp., a special purpose acquisition company. From 1996 to 2003, Mr. Pangia was self-employed as an investment banker. From 1987 to 1996, he held various senior management positions at PaineWebber, a financial services company, including Executive Vice President and Director of Investment Banking for PaineWebber Incorporated of New York, a member of the Board of Directors of PaineWebber, Inc., Chairman of PaineWebber Properties, Inc., and a member of several of PaineWebber’s executive and operating committees.

Brian Posner

Mr. Brian S. Posner is an Independent Director of Biogen Idec Inc., since July 2008. Mr. Posner has served as one of our directors since 2008. Mr. Posner has been a private investor since March 2008 and is the President of Point Rider Group LLC, a consulting and advisory services firm serving predominantly the financial services industry, as well as institutional investors seeking to make control investments in that industry. From 2005 to March 2008, Mr. Posner served as the President, Chief Executive Officer, and co-Chief Investment Officer of ClearBridge Advisors LLC, an asset management company and a wholly-owned subsidiary of Legg Mason. Prior to that, Mr. Posner co-founded Hygrove Partners LLC, a private investment fund, in 2000 and served as its Managing Partner for five years. He served as a portfolio manager and an analyst at Fidelity Investments, a financial services company, from 1987 to 1996 and, from 1997 to 1999, at Warburg Pincus Asset Management/Credit Suisse Asset Management where he also served as co-Chief Investment Officer and Director of Research.

Eric Rowinsky

Dr. Eric K. Rowinsky, M.D. is an Independent Director of the Company. Dr. Rowinsky has served as one of our directors since 2010. He has served as President of RGenix, Inc., a privately-held life sciences company, since November 2015 and as its Executive Chairman since December 2015. From January 2012 to November 2015, Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital.

Lynn Schenk

Ms. Lynn Schenk, J.D. is an Independent Director of the Company. Ms. Schenk served as a director of the Company from 1995 to 2003 during the period the Company was operated as IDEC Pharmaceuticals, and has served as a director since 2003 following IDEC’s merger with Biogen Inc. Ms. Schenk is an attorney and consultant in private practice with extensive public policy and business experience. She is also a member of the Board of Overseers of the Scripps Research Institute, a director of the California High Speed Rail Authority Board, and a trustee of the University of California, San Diego Foundation. From 1999 to 2003, she served as Chief of Staff to the Governor of California, during which time she led the effort to create the Institutes for Science and Innovation at the University of California. She headed the State’s Executive Branch risk management team post 9/11 and during the California energy crisis. From 1993 to 1995, Ms. Schenk was a Member of the United States House of Representatives, representing San Diego, California and served on the House Energy & Commerce Committee with a special emphasis on biotechnology. From 1980 to 1983, she was the California Secretary of Business, Transportation and Housing during which time she formed the California Commission on Industrial Innovation. Ms. Schenk is a member of the Board of Directors of Sempra Energy, an energy services and development company, and serves on the Compensation Committee and Environmental Health, Safety and Technology Committee of which she is the Chair.

Stephen Sherwin

Dr. Stephen A. Sherwin, M.D. is the Independent Director of Biogen Idec Inc., since March 2010. Dr. Sherwin has served as one of our directors since 2010. Dr. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at San Francisco General Hospital. Dr. Sherwin also currently serves as a venture partner with Third Rock Ventures, LLC. Dr. Sherwin previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009, he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company’s merger with BioSante Pharmaceuticals, Inc. in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. Dr. Sherwin is a member of the Boards of Directors of Neurocrine Biosciences, Inc., Rigel Pharmaceuticals, Inc., and Aduro Biotech, Inc., all of which are clinical-stage life sciences companies. During the past five years, Dr. Sherwin also served as a director of BioSante Pharmaceuticals until its merger with ANI Pharmaceuticals, Inc. in September 2013, Vical Inc., and Verastem Inc.